1. Home
  2. AGIO vs WD Comparison

AGIO vs WD Comparison

Compare AGIO & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.25

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Walker & Dunlop Inc

WD

Walker & Dunlop Inc

HOLD

Current Price

$51.55

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
WD
Founded
2007
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
AGIO
WD
Price
$27.25
$51.55
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$38.88
$76.00
AVG Volume (30 Days)
1.3M
188.4K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
5.34%
EPS Growth
N/A
N/A
EPS
N/A
1.64
Revenue
$43,011,000.00
$1,234,306,000.00
Revenue This Year
$76.75
$20.60
Revenue Next Year
$170.73
$7.79
P/E Ratio
N/A
$31.15
Revenue Growth
N/A
8.99
52 Week Low
$22.24
$42.12
52 Week High
$46.00
$90.00

Technical Indicators

Market Signals
Indicator
AGIO
WD
Relative Strength Index (RSI) 43.00 59.59
Support Level $26.03 $48.44
Resistance Level $29.69 $52.44
Average True Range (ATR) 1.36 1.57
MACD -0.19 0.23
Stochastic Oscillator 25.72 70.50

Price Performance

Historical Comparison
AGIO
WD

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About WD Walker & Dunlop Inc

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

Share on Social Networks: